论文部分内容阅读
目的分析丹参川芎嗪注射液与替罗非班联合用药方案治疗急性ST段抬高型心肌梗死的临床疗效,为临床合理用药提供参考。方法研究对象选取本院2013年9月至2015年8月收治的84例急性ST段抬高型心肌梗死患者,应用电脑随机的方式将其分为实验组与参照组各42例。参照组患者单独应用替罗非班静脉滴注治疗;实验组患者在此基础上给予丹参川芎嗪注射液进行治疗。连续6d之后对两组患者的实验室指标、不良预后发生率进行观察对比。结果两组患者的肌酸激酶、乳酸脱氢酶等指标均下降,实验组指标更优,对比差异结果显著(P<0.05);直到出院阶段,实验组患者不良预后的发生率低于参照组,对比组间差异同样具有统计学意义(P<0.05)。两组治疗期间未见明显不良反应。结论丹参川芎嗪注射液与替罗非班联合用药方案治疗急性ST段抬高型心肌梗死的疗效由于单独应用替罗非班,且安全性也较高,值得推广。
Objective To analyze the curative effect of Salviae miltiorrhizae ligustrazine injection combined with tirofiban in the treatment of acute ST-segment elevation myocardial infarction (MI), and to provide reference for clinical rational drug use. METHODS Subjects Eighty-four patients with acute ST-elevation myocardial infarction who were admitted to our hospital from September 2013 to August 2015 were randomly divided into two groups: experimental group (n = 42) and reference group (n = 42). Patients in the reference group were treated with intravenous infusion of tirofiban alone. Patients in the experimental group were given Salviae miltiorrhizae ligustrazine injection on this basis. Six consecutive days after the two groups of laboratory indicators, the incidence of adverse prognosis were observed and compared. Results The indexes of creatine kinase and lactate dehydrogenase in both groups decreased, and the experimental group had better indexes and the difference was significant (P <0.05). Until the discharge stage, the incidence of adverse prognosis in the experimental group was lower than that in the reference group , The differences between the control groups also have statistical significance (P <0.05). No significant adverse reactions during the two groups during treatment. Conclusion The efficacy of Salviae miltiorrhizae ligustrazine injection combined with tirofiban in the treatment of acute ST-segment elevation myocardial infarction is worthy of popularization due to its unique application of tirofiban and its safety.